WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of Understanding (MoUs) with NEOM and the Saudi Ministry of Health. The agreements aim to deepen the company’s footprint in Saudi Arabia by localizing new‑drug research, development, and manufacturing services, and by building a robust pharmaceutical industry value chain.

Key Elements of the NEOM Collaboration

• Localized R&D & Manufacturing – WuXi AppTec will work with NEOM to establish state‑of‑the‑art facilities for drug discovery, pre‑clinical development, and commercial production within Saudi Arabia.
• Innovation Hub – The partnership intends to create a high‑tech ecosystem that attracts global pharma partners, accelerates clinical development, and reduces time‑to‑market for novel therapeutics.

Saudi Ministry of Health MoU Highlights

• Industry Value‑Chain Localization – The MoU focuses on moving the entire pharmaceutical value chain—manufacturing, packaging, and distribution—closer to the end‑user within the Kingdom.
• Talent Development & FDI Attraction – WuXi AppTec will collaborate on large‑scale cultivation of local pharma talent and will support Saudi Arabia’s goal of boosting foreign direct investment (FDI) in the life‑sciences sector.
• Regulatory Alignment – Joint efforts will streamline regulatory pathways, ensuring that Saudi‑localized products meet both local and international standards.

Strategic Impact

• Market Expansion – The agreements position WuXi AppTec as a key partner in the rapidly growing Saudi pharmaceutical market, offering a platform for other global companies to enter the region.
• Economic Growth – By creating jobs and fostering technology transfer, the MoUs are expected to contribute significantly to Saudi Arabia’s Vision 2030 objectives of diversifying the economy and strengthening the health sector.

Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech